184 related articles for article (PubMed ID: 22012120)
1. High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM Database@Taiwan.
Chang SS; Huang HJ; Chen CY
Mol Biosyst; 2011 Dec; 7(12):3366-74. PubMed ID: 22012120
[TBL] [Abstract][Full Text] [Related]
2. Screening from the world's largest TCM database against H1N1 virus.
Chang TT; Sun MF; Chen HY; Tsai FJ; Fisher M; Lin JG; Chen CY
J Biomol Struct Dyn; 2011 Apr; 28(5):773-86. PubMed ID: 21294588
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibitor design against H1N1 swine influenza: structure-based and molecular dynamics analysis for M2 inhibitors from traditional Chinese medicine database.
Lin CH; Chang TT; Sun MF; Chen HY; Tsai FJ; Chang KL; Fisher M; Chen CY
J Biomol Struct Dyn; 2011 Feb; 28(4):471-82. PubMed ID: 21142218
[TBL] [Abstract][Full Text] [Related]
4. Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine.
Chang SS; Huang HJ; Chen CY
PLoS Comput Biol; 2011 Dec; 7(12):e1002315. PubMed ID: 22215997
[TBL] [Abstract][Full Text] [Related]
5. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
Liu H; Yao X; Wang C; Han J
Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
[TBL] [Abstract][Full Text] [Related]
6. Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.
Duwe SC; Wedde M; Birkner P; Schweiger B
Antiviral Res; 2011 Jan; 89(1):115-8. PubMed ID: 21070812
[TBL] [Abstract][Full Text] [Related]
7. Ligand-based dual target drug design for H1N1: swine flu--a preliminary first study.
Chen CY; Chang YH; Bau DT; Huang HJ; Tsai FJ; Tsai CH; Chen CY
J Biomol Struct Dyn; 2009 Oct; 27(2):171-8. PubMed ID: 19583443
[TBL] [Abstract][Full Text] [Related]
8. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
Baranovich T; Saito R; Suzuki Y; Zaraket H; Dapat C; Caperig-Dapat I; Oguma T; Shabana II; Saito T; Suzuki H;
J Clin Virol; 2010 Jan; 47(1):23-8. PubMed ID: 19962344
[TBL] [Abstract][Full Text] [Related]
9. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy.
Matsubara T; Onishi A; Saito T; Shimada A; Inoue H; Taki T; Nagata K; Okahata Y; Sato T
J Med Chem; 2010 Jun; 53(11):4441-9. PubMed ID: 20476787
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus.
Rungrotmongkol T; Intharathep P; Malaisree M; Nunthaboot N; Kaiyawet N; Sompornpisut P; Payungporn S; Poovorawan Y; Hannongbua S
Biochem Biophys Res Commun; 2009 Jul; 385(3):390-4. PubMed ID: 19463784
[TBL] [Abstract][Full Text] [Related]
11. Genetic characterization of circulating seasonal Influenza A viruses (2005-2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India.
Agrawal AS; Sarkar M; Ghosh S; Roy T; Chakrabarti S; Lal R; Mishra AC; Chadha MS; Chawla-Sarkar M
Infect Genet Evol; 2010 Dec; 10(8):1188-98. PubMed ID: 20678590
[TBL] [Abstract][Full Text] [Related]
12. Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan.
Yang JR; Huang YP; Lin YC; Su CH; Kuo CY; Hsu LC; Wu HS; Liu MT
Antiviral Res; 2010 Dec; 88(3):256-62. PubMed ID: 20869989
[TBL] [Abstract][Full Text] [Related]
13. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
Park JW; Jo WH
J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
[TBL] [Abstract][Full Text] [Related]
14. Binding mode analysis of anti-influenza drugs in H1N1 (2009) and H5N1 influenza A virus and designing of potential H1N1 inhibitors.
Singh KhD; Kirubakaran P; Nagamani S; Karthikeyan M
Int J Comput Biol Drug Des; 2015; 8(1):1-18. PubMed ID: 25869316
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening of potential inhibitors from TCM for the CPSF30 binding site on the NS1A protein of influenza A virus.
Ai H; Zhang L; Chang AK; Wei H; Che Y; Liu H
J Mol Model; 2014 Mar; 20(3):2142. PubMed ID: 24562912
[TBL] [Abstract][Full Text] [Related]
16. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1.
Renaud C; Kuypers J; Englund JA
J Clin Virol; 2011 Oct; 52(2):70-8. PubMed ID: 21684202
[TBL] [Abstract][Full Text] [Related]
17. Molecular prediction of oseltamivir efficiency against probable influenza A (H1N1-2009) mutants: molecular modeling approach.
Rungrotmongkol T; Malaisree M; Nunthaboot N; Sompornpisut P; Hannongbua S
Amino Acids; 2010 Jul; 39(2):393-8. PubMed ID: 20037767
[TBL] [Abstract][Full Text] [Related]
18. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
19. Molecular evolution of human influenza A viruses in a local area during eight influenza epidemics from 2000 to 2007.
Zaraket H; Saito R; Sato I; Suzuki Y; Li D; Dapat C; Caperig-Dapat I; Oguma T; Sasaki A; Suzuki H
Arch Virol; 2009; 154(2):285-95. PubMed ID: 19153639
[TBL] [Abstract][Full Text] [Related]
20. The potential for multidrug-resistant influenza.
van der Vries E; Schutten M; Boucher CA
Curr Opin Infect Dis; 2011 Dec; 24(6):599-604. PubMed ID: 22001947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
